Uncommon mold infections in hematological patients: Epidemiology, diagnosis and treatment

Expert Review of Anti-Infective Therapy

Volumn 9, Issue 7, 2011, Pages 881-892

  Caira, Morena ^a   Trecarichi, Enrico Maria ^a   Mancinelli, Mario ^a   Leone, Giuseppe ^a   Pagano, Livio ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

epidemiology; fusariosis; hematological patients; mucormycosis; scedosporiosis; uncommon mold infection

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; CASPOFUNGIN; DEFERASIROX; DEFEROXAMINE; ECHINOCANDIN; FLUCONAZOLE; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; KETOCONAZOLE; POSACONAZOLE; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ASPERGILLOSIS; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; FUNGUS CULTURE; FUSARIOSIS; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IMMUNOCOMPROMISED PATIENT; INCIDENCE; INFECTION RISK; MALIGNANT NEOPLASTIC DISEASE; MORBIDITY; MORTALITY; MUCORMYCOSIS; MYCOSIS; NEUTROPENIA; NONHUMAN; POLYMERASE CHAIN REACTION; PSEUDALLESCHERIASIS; QUANTITATIVE DIAGNOSIS; REVIEW; SALVAGE THERAPY;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; FUNGI; FUSARIOSIS; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; INCIDENCE; ITALY; MALE; MUCORMYCOSIS; OPPORTUNISTIC INFECTIONS; RISK FACTORS;

EID: 79961189587     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.11.66     Document Type: Review

References (99)

1. Kantarjian H, O'Brien S, Cortes J et al. Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer 113, 1933-1952 (2008).
2. Thursky KA, Worth LJ, Seymour JF, Miles Prince H, Slavin MA. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. Br. J. Haematol. 132(1), 3-12 (2006). (Pubitemid 43381565)
3. Wallis RS. Infectious complications of tumor necrosis factor blockade. Curr. Opin. Infect. Dis. 22, 403-409 (2009).
4. Kontoyiannis DP, Lionakis MS, Lewis RE et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J. Infect. Dis. 191, 1350-1360 (2005).
5. Trifilio SM, Bennett CL, Yarnold PR et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant. 39, 425-429 (2007). (Pubitemid 46487308)
6. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin. Microbiol. Rev. 13(2), 236-301 (2000). (Pubitemid 30205427)
7. Bethge WA, Schmalzing M, Stuhler G et al. Mucormycoses in patients with hematologic malignancies: an emerging fungal infection. Haematol. 90, ECR22 (2005).
8. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 34(7), 909-917 (2002). (Pubitemid 34229758)
9. Roden MM, Zaoutis TE, Buchanan WL et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin. Infect. Dis. 41(5), 634-653 (2005). (Pubitemid 41170352)
10. Caillot D, Couaillier JF, Bernard A et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J. Clin. Oncol. 19, 253-259 (2001). (Pubitemid 32063503)
11. Wahba H, Truong MT, Lei X, Kontoyiannis DP, Marom EM. Reversed halo sign in invasive pulmonary fungal infections. Clin. Infect. Dis. 46(11), 1733-1737 (2008). (Pubitemid 351706772)
12. Tarrand JJ, Lichterfeld M, Warraich I et al. Diagnosis of invasive septate mold infections. A correlation of microbiological culture and histologic or cytologic examination. Am. J. Clin. Pathol. 119, 854-858 (2003). (Pubitemid 37047847)
13. Bialek R, Konrad F, Kern J et al. PCR based identification and discrimination of agents of mucormycosis and aspergillosis in paraffin wax embedded tissue. J. Clin. Pathol. 58, 1180-1184 (2005). (Pubitemid 41566463)
14. Rickerts V, Mousset S, Lambrecht E et al. Comparison of histopathological analysis, culture, and polymerase chain reaction assays to detect invasive mold infections from biopsy specimens. Clin. Infect. Dis. 44(8), 1078-1083 (2007). (Pubitemid 46580276)
15. Lass-Flörl C, Resch G, Nachbaur D et al. The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. Clin. Infect. Dis. 45(7), e101-e104 (2007). (Pubitemid 47580399)
16. Bodey GP. Infectious complications of acute leukemia. Med. Times 94(9), 1076-1085 (1966).
17. Bullen JJ, Rogers HJ, Spalding PB, Ward CG. Iron and infection: the heart of the matter. FEMS Immunol. Med. Microbiol. 43, 325-330 (2005). (Pubitemid 40228944)
18. Maertens J, Demuynck H, Verbeken EK et al. Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplant. 24, 307-312 (1999). (Pubitemid 29377872)
19. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 100, 4358-4366 (2002). (Pubitemid 35429674)
20. Baddley JW, Stroud TP, Salzman D, Pappas PG. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin. Infect. Dis. 32, 1319-1324 (2001). (Pubitemid 32405904)
21. Martino R, Subirá M, Rovira M et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br. J. Haematol. 116, 475-482 (2002). (Pubitemid 34155525)
22. Fukuda T, Boeckh M, Carter RA et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 102, 827-833 (2003). (Pubitemid 36917771)
23. Pagano L, Caira M, Nosari A et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study - Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin. Infect. Dis. 45(9), 1161-1170 (2007). (Pubitemid 47580314)
24. Garcia-Vidal C, Upton A, Kirby KA, Marr KA. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin. Infect. Dis. 47, 1041-1050 (2008).
25. Neofytos D, Horn D, Anaissie E et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin. Infect. Dis. 48, 265-273 (2009).
26. Kontoyiannis DP, Marr KA, Park BJ et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin. Infect. Dis. 50, 1091-1100 (2010).
27. Pagano L, Girmenia C, Mele L et al. Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA Infection Program. Haematologica 86(8), 862-870 (2001). (Pubitemid 32847449)
28. Nosari A, Oreste P, Montillo M et al. Mucormycosis in hematologic malignancies: an emerging fungal infection. Haematologica 85(10), 1068-1071 (2000).
29. Pagano L, Caira M, Candoni A et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 91(8), 1068-1075 (2006). (Pubitemid 44208634)
30. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N. Engl. J. Med. 350, 950-952 (2004). (Pubitemid 38252550)
31. Bitar D, Van Cauteren D, Lanternier F et al. Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerg. Infect. Dis. 15(9), 1395-1401 (2009).
32. Rüping MJ, Heinz WJ, Kindo AJ et al. Forty-one recent cases of invasive zygomycosis from a global clinical registry. J. Antimicrob. Chemother. 65(2), 296-302 (2010).
33. Pagano L, Offidani M, Fianchi L et al. Mucormycosis in hematologic patients. Haematologica 89, 207-214 (2004). (Pubitemid 38796496)
34. Pagano L, Valentini CG, Posteraro B et al. Zygomycosis in Italy: a survey of FIMUA-ECMM (Federazione Italiana di Micopatologia Umana ed Animale and European Confederation of Medical Mycology).J. Chemother. 21, 322-329 (2009).
35. Ambrosioni J, Bouchuiguir-Wafa K, Garbino J. Emerging invasive zygomycosis in a tertiary care center: epidemiology and associated risk factors. Int. J. Infect. Dis. 14(Suppl. 3), e100-e103 (2010).
36. Saegeman V, Maertens J, Meersseman W, Spriet I, Verbeken E, Lagrou K. Increasing incidence of mucormycosis in University Hospital, Belgium. Emerg. Infect. Dis. 16(9), 1456-1458 (2010).
37. Meis JF, Chakrabarti A. Changing epidemiology of an emerging infection: zygomycosis. Clin. Microbiol. Infect. 15(Suppl. 5), 10-14 (2009).
38. Chakrabarti A, Das A, Mandal J et al. The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Med. Mycol. 44(4), 335-342 (2006). (Pubitemid 43922068)
39. Kontoyiannis DP. Decrease in the number of reported cases of zygomycosis among patients with diabetes mellitus: a hypothesis. Clin. Infect. Dis. 44(8), 1089-1090 (2007). (Pubitemid 46580278)
40. Diwakar A, Dewan RK, Chowdhary A, Randhawa HS, Khanna G, Gaur SN. Zygomycosis-a case report and overview of the disease in India. Mycoses 50(4), 247-254 (2007). (Pubitemid 46920279)
41. Chakrabarti A, Das A, Sharma A et al. Ten years' experience in zygomycosis at a tertiary care centre in India. J. Infect. 42(4), 261-266 (2001). (Pubitemid 32700823)
42. Skiada A, Pagano L, Groll A et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin. Microbiol. Infect. DOI: 10.1111/j.1469-0691.2010.03456.x. (2011) (Epub ahead of print).
43. Kara IO, Tasova Y, Uguz A, Sahin B. Mucormycosis-associated fungal infections in patients with haematologic malignancies. Int. J. Clin. Pract. 63(1), 134-139 (2009).
44. Zaoutis TE, Roilides E, Chiou CC et al. Zygomycosis in children: a systematic review and analysis of reported cases. Pediatr. Infect. Dis. J. 26(8), 723-727 (2007). (Pubitemid 47424643)
45. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin. Infect. Dis. 30, 851-856 (2000). (Pubitemid 32250321)
46. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin. Infect. Dis. 47, 503-509 (2008).
47. Adler-Moore J, Proffitt RT. Effect of tissue penetration on AmBisome efficacy. Curr. Opin. Investig. Drugs. 4, 179-185 (2003). (Pubitemid 36383014)
48. Pagano L, Ricci P, Tonso A et al. Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases. GIMEMA Infection Program (Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto).Br. J. Haematol. 99, 331-336 (1997).
49. Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob. Agents Chemother. 46(5), 1581-1582 (2002). (Pubitemid 34415351)
50. Greenberg RN, Mullane K, van Burik JA et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob. Agents Chemother. 50, 126-133 (2006). (Pubitemid 43042912)
51. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin. Infect. Dis. 42, e61-e65 (2006).
52. Reed C, Bryant R, Ibrahim AS et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin. Infect. Dis. 47, 364-371 (2008). (Pubitemid 352009357)
53. Price TH, Bowden RA, Boeckh M et al. Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation. Blood 95(11), 3302-3309 (2000). (Pubitemid 30428457)
54. Mousset S, Hermann S, Klein SA et al. Prophylactic and interventional granulocyte transfusions in patients with haematological malignancies and life-threatening infections during neutropenia. Ann. Hematol. 84(11), 734-741 (2005). (Pubitemid 41447808)
55. John BV, Chamilos G, Kontoyiannis DP. Hyperbaric oxygen as an adjunctive treatment for zygomycosis. Clin. Microbiol. Infect. 11(7), 515-517 (2005). (Pubitemid 40895150)
56. Reed C, Ibrahim A, Edwards JE Jr, Walot I, Spellberg B. Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob. Agents Chemother. 50(11), 3968-3969 (2006). (Pubitemid 44684931)
57. Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin. Microbiol. Rev. 20(4), 695-704 (2007). (Pubitemid 47623773)
58. Martino P, Gastaldi R, Raccah R, Girmenia C. Clinical patterns of Fusarium infections in immunocompromised patients. J. Infect. 28(Suppl. 1), 7-15 (1994).
59. Nucci M, Marr KA, Queiroz-Telles F et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 38(9), 1237-1242 (2004). (Pubitemid 38608564)
60. Campo M, Lewis RE, Kontoyiannis DP. Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998-2009. J. Infect. 60(5), 331-337 (2010).
61. Cornely OA. Aspergillus to Zygomycetes: causes, risk factors, prevention, and treatment of invasive fungal infections. Infection 36(4), 296-313 (2008).
62. Girmenia C, Pagano L, Corvatta L, Mele L, del Favero A, Martino P. The epidemiology of fusariosis in patients with haematological diseases. Gimema Infection Programme. Br. J. Haematol. 111(1), 272-276 (2000).
63. Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 90(3), 999-1008 (1997). (Pubitemid 27314133)
64. Nucci M, Anaissie EJ, Queiroz-Telles F et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer 98(2), 315-319 (2003). (Pubitemid 36828456)
65. Walsh TJ, Hiemenz JW, Seibel NL et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin. Infect. Dis. 26(6), 1383-1396 (1998). (Pubitemid 28270170)
66. Perfect JR. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. Clin. Infect. Dis. 40(Suppl. 6), S401-S408 (2005). (Pubitemid 40563297)
67. Raad II, Hachem RY, Herbrecht R et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin. Infect. Dis. 42(10), 1398-1403 (2006).
68. Perfect JR, Marr KA, Walsh TJ et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin. Infect. Dis. 36(9), 1122-1131 (2003). (Pubitemid 36549632)
69. Azor M, Gené J, Cano J, Guarro J. Universal in vitro antifungal resistance of genetic clades of the Fusarium solani species complex. Antimicrob. Agents Chemother. 51(4), 1500-1503 (2007). (Pubitemid 46586837)
70. Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, Rex JH. In vitro activities of investigational triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results. Antimicrob. Agents Chemother. 46(10), 3298-3300 (2002).
71. Tortorano AM, Prigitano A, Dho G et al. Species distribution and in vitro antifungal susceptibility patterns of 75 clinical isolates of Fusarium spp. from northern Italy. Antimicrob. Agents Chemother. 52(7), 2683-2685 (2008). (Pubitemid 351915710)
72. Lortholary O, Obenga G, Biswas P et al. International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob. Agents Chemother. 54(10), 4446-4450 (2010).
73. Hsiue HC, Ruan SY, Kuo YL, Huang YT, Hsueh PR. Invasive infections caused by non-Aspergillus moulds identified by sequencing analysis at a tertiary care hospital in Taiwan, 2000-2008. Clin. Microbiol. Infect. 16(8), 1204-1206 (2010).
74. Dignani MC, Anaissie E. Human fusariosis. Clin. Microbiol. Infect. 10(Suppl. 1), 67-75 (2004). (Pubitemid 38379952)
75. Anaissie EJ, Stratton SL, Dignani MC et al. Pathogenic molds (including Aspergillus species) in hospital water distribution systems: a 3-year prospective study and clinical implications for patients with hematologic malignancies. Blood 101(7), 2542-2546 (2003). (Pubitemid 36857610)
76. Steinbach WJ, Perfect JR. Scedosporium species infections and treatments. J. Chemother. 15(Suppl. 2), 16-27 (2003). (Pubitemid 38021612)
77. Berenguer J, Rodríguez-Tudela JL, Richard C et al. Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature. Scedosporium prolificans Spanish Study Group. Medicine. 76(4), 256-265 (1997).
78. Rodriguez-Tudela JL, Berenguer J, Guarro J et al. Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases. Med. Mycol. 47(4), 359-370 (2009).
79. Caira M, Girmenia C, Valentini CG et al. Scedosporiosis in patients with acute leukemia: a retrospective multicenter report. Haematol. 93(1), 104-110 (2008). (Pubitemid 351187612)
80. Idigoras P, Pérez-Trallero E, Piñeiro L et al. Disseminated infection and colonization by Scedosporium prolificans: a review of 18 cases, 1990-1999. Clin. Infect. Dis. 32(11), E158-E165 (2001).
81. Lionakis MS, Bodey GP, Tarrand JJ, Raad II, Kontoyiannis DP. The significance of blood cultures positive for emerging saprophytic moulds in cancer patients Clin. Microbiol. Infect. 10(10), 922-925 (2004). (Pubitemid 39405841)
82. Kimura M, Maenishi O, Ito H, Ohkusu K. Unique histological characteristics of Scedosporium that could aid in its identification. Pathol. Int. 60(2), 131-136 (2010).
83. Cortez KJ, Roilides E, Quiroz-Telles F et al. Infections caused by Scedosporium spp. Clin. Microbiol. Rev. 21(1), 157-197 (2008).
84. Castelli MV, Buitrago MJ, Bernal- Martinez L, Gomez-Lopez A, Rodriguez- Tudela JL, Cuenca-Estrella M. Development and validation of a quantitative PCR assay for diagnosis of scedosporiosis. J. Clin. Microbiol. 46(10), 3412-3416 (2008).
85. Malloch D, Salkin IA. A new species of Scedosporium associated with osteomyelitis in humans. Mycotaxon 21, 247-255 (1984).
86. Wright JH. A case of Madura foot. J. Boston Soc. Med. Sci. 2(8),128-130.1 (1898).
87. Lamaris GA, Chamilos G, Lewis RE, Safdar A, Raad II, Kontoyiannis DP. Scedosporium infection in a tertiary care cancer center: a review of 25 cases from 1989-2006. Clin. Infect. Dis. 43(12), 1580-1584 (2006). (Pubitemid 44901901)
88. Cooley L, Spelman D, Thursky K, Slavin M. Infection with Scedosporium apiospermum and S. prolificans, Australia. Emerg. Infect. Dis. 13(8), 1170-1177 (2007). (Pubitemid 47359160)
89. Husain S, Muñoz P, Forrest G et al. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin. Infect. Dis. 40(1), 89-99 (2005). (Pubitemid 40053464)
90. Tintelnot K, Just-Nübling G, Horré R et al. A review of German Scedosporium prolificans cases from 1993 to 2007. Med. Mycol. 47(4), 351-358 (2009).
91. Grenouillet F, Botterel F, Crouzet J et al. Scedosporium prolificans: an emerging pathogen in France? Med. Mycol. 47(4), 343-350 (2009).
92. Heath CH, Slavin MA, Sorrell TC. Population-based surveillance for scedosporiosis in Australia: epidemiology, disease manifestations and emergence of Scedosporium aurantiacum infection. Clin. Microbiol. Infect. 15(7), 689-693 (2009).
93. Meletiadis J, Meis JF, Mouton JW, Rodriquez-Tudela JL, Donnelly JP, Verweij PE; EUROFUNG Network. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob. Agents Chemother. 46(1), 62-68 (2002). (Pubitemid 34031603)
94. Gilgado F, Serena C, Cano J, Gené J, Guarro J. Antifungal susceptibilities of the species of the Pseudallescheria boydii complex. Antimicrob. Agents Chemother. 50(12), 4211-4213 (2006). (Pubitemid 44865174)
95. Troke P, Aguirrebengoa K, Arteaga C et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob. Agents Chemother. 52(5), 1743-1750 (2008). (Pubitemid 351614668)
96. Howden BP, Slavin MA, Schwarer AP, Mijch AM. Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur. J. Clin. Microbiol. Infect. Dis. 22(2), 111-113 (2003). (Pubitemid 36349974)
97. Gosbell IB, Toumasatos V, Yong J, Kuo RS, Ellis DH, Perrie RC. Cure of orthopaedic infection with Scedosporium prolificans, using voriconazole plus terbinafine, without the need for radical surgery. Mycoses 46(5-6), 233-236 (2003). (Pubitemid 36808246)
98. Das S, Saha R, Dar SA, Ramachandran VG. Acremonium species: a review of the etiological agents of emerging hyalohyphomycosis. Mycopathologia. 170(6), 361-375 (2010).
99. Schinabeck MK, Ghannoum MA. Human hyalohyphomycoses: a review of human infections due to Acremonium spp., Paecilomyces spp., Penicillium spp., and Scopulariopsis spp. J. Chemother. 15(Suppl. 2), 5-15 (2003). (Pubitemid 38021611)